On December 12, 2025, VYNE Therapeutics Inc. held its annual meeting, where 50.1% of shares voted, electing two directors and ratifying Baker Tilly US, LLP as auditors for 2024; stockholders also approved executive compensation with 4.57 million votes in favor.